RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) — RayzeBio, Inc. (Nasdaq:RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today reported financial results for the third quarter ended September 30, 2023 and provided an update on key corporate initiatives.
Related news for (RYZB)
- Pancreatic Cancer Treatments Poised for Major Advances in 2024
- SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates RYZB, FGH, AXNX, AMAM
- SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates KRTX, RYZB, VIA
- SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates GRCL, RYZB, CPE, BRBS
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RYZB, KRTX, GRCL